Novel targets for lung cancer therapy: part I.
Lung cancer is the second most common form of cancer in the United States, and although it accounts for 15% of all cancers, it is the most lethal, accounting for approximately 28% of cancer deaths. In 2002, it is estimated that 177,000 new cases of lung cancer will be diagnosed in the United States, and an estimated 160,000 men and women will die from the disease. This mortality rate is greater than that attributable to colorectal, breast, and prostate cancer combined. Systemic treatments for lung cancer with standard chemotherapy agents are still relatively ineffective. Agents targeting novel proliferative and survival pathways in lung cancer are needed to improve treatment outcomes. In recent years, numerous agents inhibiting aberrant processes in tumor cells have undergone clinical evaluation. This review is the first of a two-part series that summarizes pertinent preclinical and clinical information on novel drugs that target critical abnormalities in lung cancer. In this article, agents inhibiting growth factor receptors and various molecules downstream of activated signaling cascades, such as cytoplasmic second messengers, are described.
Dy
Grace K
GK
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Adjei
Alex A
AA
D004358:Drug Therapy / Q000639:trends; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology*; D015290:Second Messenger Systems / Q000187:drug effects*; D015398:Signal Transduction
D017978:Receptors, Growth Factor